[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
FDA- and EMA-Approved Tyrosine Kinase Inhibitors in Advanced EGFR-Mutated Non-Small Cell Lung Cancer: Safety, Tolerability, Plasma Concentration Monitoring …
I Solassol, F Pinguet, X Quantin - Biomolecules, 2019 - mdpi.com
Non-small-cell lung cancer (NSCLC) is the most common form of primary lung cancer. The
discovery of several oncogenic driver mutations in patients with NSCLC has allowed the …
discovery of several oncogenic driver mutations in patients with NSCLC has allowed the …
[HTML][HTML] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the …
X Wang, D Goldstein, PJ Crowe… - OncoTargets and …, 2016 - Taylor & Francis
Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptor
(EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non …
(EGFR/HER) family have been introduced into the clinic to treat cancers, particularly non …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
KSH Nguyen, JW Neal - Biologics: Targets and Therapy, 2012 - Taylor & Francis
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) were initially
established as second-or third-line treatment of advanced non-small-cell lung cancer …
established as second-or third-line treatment of advanced non-small-cell lung cancer …
Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L
Y Urata, N Katakami, S Morita, R Kaji… - Journal of Clinical …, 2016 - ascopubs.org
Purpose The epidermal growth factor receptor (EGFR) tyrosine kinase has been an
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
important target for non–small-cell lung cancer. Several EGFR tyrosine kinase inhibitors …
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
LV Sequist, RG Martins, D Spigel… - Journal of clinical …, 2008 - ascopubs.org
Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
Outcomes of first-generation EGFR-TKIs against non-small-cell lung cancer harboring uncommon EGFR mutations: a post hoc analysis of the BE-POSITIVE study
S Pilotto, A Rossi, T Vavalà, A Follador, M Tiseo… - Clinical Lung Cancer, 2018 - Elsevier
Background Beyond progression after tyrosine kinase inhibitor in EGFR-positive non-small-
cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study …
cell lung cancer patients (BE-POSITIVE) was the first Italian multicenter observational study …
Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
L Paz‐Ares, D Soulières, I Melezínek… - Journal of cellular …, 2010 - Wiley Online Library
Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …